Faculty

Georgiana K. Ellis, MD

Georgiana K. Ellis, MD

Associate Professor
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G3630
Seattle, WA 98109-1023

Admin Contact

Audrey Monroe
206.288.6989
amonroe@seattlecca.org
Fax: 206.288.2054

Specialty / Expertise

Breast cancer

Research Interests

  • Dose intensity in breast cancer treatment
  • Maximizing treatment effectiveness and minimizing side effects
  • Long term quality of life

Current Research Projects

N/A

Training

Dr. Ellis received her MD from the University of Washington, Seattle, WA. She completed her Internal Medicine Residency at the University of Washington, Seattle, WA. She was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, WA.

Selected Publications

Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin-Seymour MM.  Concurrent  radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.  Int J Rad Onc Biol Phys 2000;48(2):393-397.

Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, Austin-Seymour MM, Funkhouser CP, Livingston  RB.  [F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) to Detect Mediastinal or Internal Mammary (IM) Metastases in Breast Cancer.  J Clin Oncol 2001;19:3516-3523.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RL.  Blood Flow and Metabolism in Locally Advanced Breast Cancer:  Relationship to Response to Therapy.  J Nuclear Med 2002;43(4):500-509.

*Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T.  Dose-dense anthracycline-based chemotherapy for node positive breast cancer.  J Clin Oncol 2002;20(17):3637-3643.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, Tseng J, Rinn KJ, Livingston RB.  [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow, Nuclear Medicine and Biology 2002;29(7):719-775.

Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Ellis GK, Schubert EK, et al.  Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.  Radiographics 2002;22(1):5-17, Review.

Garrison JA, McCune JS, Livingston RB, Gralow JR, Ellis GK, West HL.  Myalgias and arthralgias associated with paclitaxel:  Incidence and management.  Oncology 2003;17(2):271-277, discussion 281-282, 286-288, Review.

Georgian-Smith D, Ellis GK, Kraft GH.  Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma.  Breast J 2003;9(4):316-318.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.  J Nucl Med 2003;44(11):1806-1814.

Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM.  HER-2 testing in breast cancer using parallel tissue-based methods.  JAMA 2004;291(16):1972-1977, editorial comment  2019.

McCune JS, Hatfield AJ, Blackburn AR, Leith PO, Livingston RB, Ellis GK.  Potential of chemotherapy-herb interactions in adult cancer patients.  Support Care Cancer 2004;12(6):454-462.

Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA.  Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).  Am J Clin Oncol 2004;27(4):407-410.

Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R.  Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.  AJR Am J Roentgenol 2004; 183(2):479-486.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE Schubert EK, Mankoff DA.  Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 2005; 103(4):680-688.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra P, Peterson LM, Schubert E, Dunnwald LK, Krohn KA, Mankoff DA.  Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment.  J Clin Oncol 2006;24(18):2793-2799.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RL, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, and Mankoff DA.  Tumor metabolism and blood flow changes by positron emission tomography:  Relation to survival among a prospective cohort of neoadjuvantly treated locally advanced breast cancer patients. J Clin Oncol 2008;26(27):4449-4457.

*Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer. J Clin Oncol 2008;26(30):4875-4882.

Slovak, ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).  Breast Cancer Res Treat 2010;119:391-398.

*GK Ellis, WE Barlow, JR Gralow, GN Hortobagyi, CA Russell, ME Royce, EA Perez, D Lew, and RB Livingston. SWOG 0012: A Randomized Phase III Comparison of Standard Doxorubicin and Cyclophosphamide versus Weekly Doxorubicin and Daily Oral Cyclophosphamide plus G-CSF as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer.  Tentatively accepted pending revision, J Clin Oncol 2010.

Specht JM, Kurland BF, Montgomery S, Dunnwald L, Doot R, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison K, Schubert E, Mankoff DA.  Tumor metabolism and blood flow as assessed by PET varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res May 15, 2010 16:2803-2810.

Dunnwald L, Doot R, Specht J, Gralow J, Ellis G, Livingston R, Linden H, Gadi V, Kurland B, Schubert E, Muzi M, Mankoff D. PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxy glucose Uptake. Clinical Cancer Research. 17(8):2400-9, 2011.

Linden H, Kurland B, Peterson L, Schubert E, Gralow J, Specht J, Ellis G, Lawton T, Livingston R, Petra P, Link J, Krohn K, Mankoff D. Fluoroestradiol (FES) Positron Emission Tomography (PET) Finds Pharmacodynamic Differences Between Estrogen Deprivation and Blockade In Metastatic Breast Cancer. Clinical Cancer Research. 17: 4799-4805, July 2011.

Last updated: April 2013

Top